Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial

Mostrar otras versiones (1)

Introduction: Severe COVID-19 pneumonia is characterised by respiratory and multi-organ failure in the context of marked systemic inflammation. This hyperinflammatory syndrome is reflected by the elevation of several inflammatory molecules, such as C-reactive protein (CRP), ferritin, IL-6, troponin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Charania, Asad, Vergis, Nikhil, Phillips, Rachel, Cornelius, Victoria, Katsarou, Alexia, Youngstein, Taryn, Cook, Lucy, Michelle, Willicombe, Pillay, Clio, Shturova, Tina, Almonte, Melanie, Turner, Richard, Kon, Onn Min, Cooke, Graham, Thursz, Mark, Cherlin, Svetlana, Wason, James, Milojkovic, Dragana, Innes, Andrew J., Cooper, Nichola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
203.Lymphocytes and Acquired or Congenital Immunodeficiency Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701438/
http://dx.doi.org/10.1182/blood-2021-148480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701438/
http://dx.doi.org/10.1182/blood-2021-148480

Ejemplares similares